Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response.
Alieva M, Barrera Román M, de Blank S, Petcu D, Zeeman AL, Dautzenberg NMM, Cornel AM, van de Ven C, Pieters R, den Boer ML, Nierkens S, Calkoen FGJ, Clevers H, Kuball J, Sebestyén Z, Wehrens EJ, Dekkers JF, Rios AC. Alieva M, et al. Among authors: van de ven c. Nat Protoc. 2024 Jul;19(7):2052-2084. doi: 10.1038/s41596-024-00972-6. Epub 2024 Mar 19. Nat Protoc. 2024. PMID: 38504137 Review.
Ibrutinib is not an effective drug in primografts of TCF3-PBX1.
van de Ven C, Boeree A, Stalpers F, Zwaan CM, Den Boer ML. van de Ven C, et al. Transl Oncol. 2020 Oct;13(10):100817. doi: 10.1016/j.tranon.2020.100817. Epub 2020 Jun 18. Transl Oncol. 2020. PMID: 32563910 Free PMC article.
JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP, Jerchel IS, de Goffau-Nobel W, Hoogkamer AQ, Boer JM, Boeree A, van de Ven C, Koudijs MJ, Besselink NJM, de Groot-Kruseman HA, Zwaan CM, Horstmann MA, Pieters R, den Boer ML. Steeghs EMP, et al. Among authors: de goffau nobel w, van de ven c, de groot kruseman ha. Oncotarget. 2017 Sep 16;8(52):89923-89938. doi: 10.18632/oncotarget.21027. eCollection 2017 Oct 27. Oncotarget. 2017. PMID: 29163799 Free PMC article.
Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I, Boer JM, van de Ven C, Reichert CEJ, Boeree A, Kruisinga B, de Groot-Kruseman HA, Escherich G, Sijs-Szabo A, Rijneveld AW, den Boer ML. van Outersterp I, et al. Among authors: van de ven c, de groot kruseman ha. Blood Adv. 2024 Apr 23;8(8):1835-1845. doi: 10.1182/bloodadvances.2023012162. Blood Adv. 2024. PMID: 38386975 Free PMC article.
RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
Jerchel IS, Hoogkamer AQ, Ariës IM, Steeghs EMP, Boer JM, Besselink NJM, Boeree A, van de Ven C, de Groot-Kruseman HA, de Haas V, Horstmann MA, Escherich G, Zwaan CM, Cuppen E, Koudijs MJ, Pieters R, den Boer ML. Jerchel IS, et al. Among authors: de haas v, van de ven c, de groot kruseman ha. Leukemia. 2018 Apr;32(4):931-940. doi: 10.1038/leu.2017.303. Epub 2017 Oct 3. Leukemia. 2018. PMID: 28972594 Free PMC article.
Cdx and Hox genes differentially regulate posterior axial growth in mammalian embryos.
Young T, Rowland JE, van de Ven C, Bialecka M, Novoa A, Carapuco M, van Nes J, de Graaff W, Duluc I, Freund JN, Beck F, Mallo M, Deschamps J. Young T, et al. Among authors: de graaff w, van de ven c, van nes j. Dev Cell. 2009 Oct;17(4):516-26. doi: 10.1016/j.devcel.2009.08.010. Dev Cell. 2009. PMID: 19853565 Free article.
Concerted involvement of Cdx/Hox genes and Wnt signaling in morphogenesis of the caudal neural tube and cloacal derivatives from the posterior growth zone.
van de Ven C, Bialecka M, Neijts R, Young T, Rowland JE, Stringer EJ, Van Rooijen C, Meijlink F, Nóvoa A, Freund JN, Mallo M, Beck F, Deschamps J. van de Ven C, et al. Among authors: van rooijen c. Development. 2011 Aug;138(16):3451-62. doi: 10.1242/dev.066118. Epub 2011 Jul 13. Development. 2011. PMID: 21752936 Free article.
Locoregional control in high-risk neuroblastoma using highly-conformal image-guided radiotherapy, with reduced margins and a boost dose for residual lesions.
Samim A, Littooij AS, Peters M, de Keizer B, van der Steeg AFW, Fajardo RD, Kraal KCJM, Dierselhuis MP, van Eijkelenburg NKA, van Grotel M, Polak R, van de Ven CP, Wijnen MHWA, Seravalli E, Willemsen-Bosman ME, van Noesel MM, Tytgat GAM, Janssens GO. Samim A, et al. Among authors: van de ven cp. Radiother Oncol. 2025 Jan;202:110604. doi: 10.1016/j.radonc.2024.110604. Epub 2024 Oct 29. Radiother Oncol. 2025. PMID: 39481605 Free article.
236 results